It is an East Windsor Township tradition to recognize businesses – how important they are to the community, how proud the township is of them and how they contribute to the community – every year, Mayor Janice Mironov said There are three awards – the Business Beautification Award, the Community Service Award and the Community […]
Developing and filing for both small-molecule and biological cancer therapies forms a key part of Aurobindo’s strategy to target higher-value products. Aidan Fry examines the company’s plan in this Generic’s bulletin Dec 2017 article.
Aurobindo aims at cancer as it climbs the value chain Read More »
East Windsor, N.J. – Aurobindo Pharma Limited has received final approval from the U.S. Food and Drug Administration for Quetiapine Fumarate Extended-Release Tablets, 50 mg, 150 mg, 200 mg, 300mg and 400mg. The Division of Bioequivalence has determined Aurobindo Pharma Limited’s Quetiapine Fumarate Extended-Release Tablets 50 mg, 150 mg, 200 mg, 300 mg, and 400
Aurobindo Receives FDA Approval for Quetiapine Fumarate Extended Release Tablets. Read More »
Frankfurt, 24 October 2017 – Aurobindo Pharma Limited and Generics Bulletin are pleased to announce that Aurobindo has won the Company of the Year, Asia-Pacific Award at the Global Generics & Biosimilars Awards 2017, organized by Generics Bulletin. The Company of the Year, Asia-Pacific Award was sponsored by Eva Pharma and judged by an expert panel. “Congratulations
East Windsor, N.J. – Aurobindo Pharma Limited has received final approval from the U.S. Food and Drug Administration for Prasugrel Tablets, 5 mg and 10 mg. The Division of Bioequivalence has determined Aurobindo Pharma Limited’s Prasugrel Tablets, 5 mg and 10 mg to be bioequivalent and, therefore, therapeutically equivalent to the reference listed drug Effient®
Aurobindo Receives FDA Approval for Prasugrel Tablets, 5 mg and 10mg Read More »
East Windsor, N.J. – Aurobindo Pharma Limited has received final approval from the U.S. Food and Drug Administration for Ezetimibe Tablets USP, 10 mg. The Division of Bioequivalence has determined Aurobindo Pharma Limited’s Ezetimibe Tablets USP, 10 mg to be bioequivalent and, therefore, therapeutically equivalent to the reference listed drug ZETIA®. Ezetimibe is indicated as
Aurobindo Receives FDA Approval for Ezetimibe Tablets USP, 10 mg Read More »
East Windsor, N.J. – Aurobindo Pharma Limited has received final approval from the U.S. Food and Drug Administration for Moxifloxacin Ophthalmic Soln. 0.5%. The Division of Bioequivalence has determined Aurobindo Pharma Limited’s Moxifloxacin Ophthalmic Soln. 0.5%. to be bioequivalent and, therefore, therapeutically equivalent to the reference listed drug Vigamox® Moxifloxacin Ophthalmic Solution is indicated as
Aurobindo Receives FDA Approval for Moxifloxacin Ophthalmic Soln. 0.5%. Read More »
East Windsor, N.J. – The new Aurobindo Distribution Center is 567,000 square ft. facility which sits on 59 acres of land in East Windsor, New Jersey. This new facility will house Aurobindo solid dosage forms as well as AuroMedics injectables and OTC product from our Aurohealth division. The inventory will be stored within a state
East Windsor, N.J. – Aurobindo Pharma Limited has received final approval from the U.S. Food and Drug Administration for Aurovela™ line of OC tablets. The Division of Bioequivalence has determined Aurobindo Pharma Limited’s Aurovela™ to be bioequivalent and, therefore, therapeutically equivalent to Loestrin® line of oral contraceptive products. Please see table below for each of
Aurobindo Receives FDA Approval for the line of OC tablets Aurovela™ Read More »
East Windsor, N.J. – Aurobindo Pharma Limited has received final approval from the U.S. Food and Drug Administration for Sevelamer Carbonate Tablets, 800 mg. The Division of Bioequivalence has determined Aurobindo Pharma Limited’s Sevelamer Carbonate Tablets, 800 mg to be bioequivalent and, therefore, therapeutically equivalent to the reference listed drug Renvela®. Sevelamer Carbonate is a
Aurobindo Receives FDA Approval for Sevelamer Carbonate Tablets, 800 mg Read More »
CitiHope offers a proven track record of successful humanitarian relief assistance worldwide, as well as substantial access to donated WHO listed pharmaceuticals. Essential to CitiHope’s medical programs is the partnership with Aurobindo Pharma USA. From 2013 to 2016 Aurobindo, through CitiHope, provided critically needed medicines to qualified healthcare institutions for over 333,000 patients worldwide. https://youtu.be/9k3bLxnnyAs
CitiHope | Critical medicines reach 333,000+ patients globally Read More »
Aurobindo’s ongoing support of Brother’s Brother Foundation allowed the organization to provide life-saving treatments to remote areas all over the world. Most recently the pharmaceuticals that were donated have been sent with partner organizations to continents all over the world. Primarily recipients are in developing economies and cover the following 19 countries specifically; Guatemala, Haiti,
Life-saving Treatments by the Help of Aurobindo Read More »